A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | stella

Learn Find trials matched to me

Learn Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy For Researchers Data Labs ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | stella

Back to Systemic Lupus Erythematosus trials

Opening soon

Plain-English translation of NCT07906145 on ClinicalTrials.gov ↗ · Source last updated October 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Key details

Phase

Safety & dosing

Sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD

Enrollment target

~76 participants

Started

December 2026

Primary completion

June 2029

Age range

18 Years – 70 Years

Last updated on clinicaltrials.gov in October 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Rong Mu

Shanghai Qilu Pharmaceutical Research and Development Center LTD

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.